Treatments for psoriasis: A journey from classical to advanced therapies. How far have we reached?

Research output: Contribution to journalReview articlepeer-review

6 Citations (Scopus)


Psoriasis is considered an autoimmune, inflammatory disorder with a genetic basis. The underlying aetiology is yet unclear. Evidence suggests the congregation of immune cells and their secreted inflammatory cytokines, leukocytes, and other inflammation-promoting factors in large amounts within the epidermal layers of the skin, driving an inflammatory milieu. Although psoriasis is not a fatal condition, patients experience severe pain and suffering. It has a debilitating effect on the physiological and psychological state of the patient. Its distinguishing features are inflammation, formation of plaques on the skin and hyperproliferation of keratinocytes. Therapeutic strategies for treating psoriasis witnessed a radical improvement from traditional therapies to the approval of specific therapies like biologics and small molecules. The emerging evidence about new pharmacological targets and mechanisms in psoriasis has widened the scope for expanding therapeutic strategies. Our review discusses the existing treatments for plaque psoriasis and updates on therapies based on novel pharmacological targets in clinical development.

Original languageEnglish
Article number175147
JournalEuropean Journal of Pharmacology
Publication statusPublished - 15-08-2022

All Science Journal Classification (ASJC) codes

  • Pharmacology


Dive into the research topics of 'Treatments for psoriasis: A journey from classical to advanced therapies. How far have we reached?'. Together they form a unique fingerprint.

Cite this